Charles S. Fuchs

Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer

Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Postmenopausal Hormone Therapy and Mortality

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men

<i>Fusobacterium nucleatum</i>in colorectal carcinoma tissue and patient prognosis

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology